Data point to role of cellular bioenergetics as a new mechanistic approach to treat immune disorders
Wednesday, January 26, 2011 - 15:30
in Health & Medicine
Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced positive data from the University of Michigan demonstrating the role of bioenergetics in selectively inhibiting pathogenic lymphocytes while preserving and enhancing the normal immune system. The findings, published online today in Science Translational Medicine, support Lycera's promising novel therapeutic approach to treating a broad spectrum of immune diseases.